1. Home
  2. OPEN vs IBRX Comparison

OPEN vs IBRX Comparison

Compare OPEN & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Opendoor Technologies Inc

OPEN

Opendoor Technologies Inc

HOLD

Current Price

$5.06

Market Cap

5.9B

Sector

Finance

ML Signal

HOLD

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$6.09

Market Cap

6.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OPEN
IBRX
Founded
2014
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
6.1B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
OPEN
IBRX
Price
$5.06
$6.09
Analyst Decision
Sell
Strong Buy
Analyst Count
3
5
Target Price
$1.67
$11.80
AVG Volume (30 Days)
61.6M
52.8M
Earning Date
02-19-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,719,000,000.00
$82,555,000.00
Revenue This Year
N/A
$680.06
Revenue Next Year
$22.96
$90.18
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1025.95
52 Week Low
$0.51
$1.83
52 Week High
$10.87
$8.28

Technical Indicators

Market Signals
Indicator
OPEN
IBRX
Relative Strength Index (RSI) 35.16 66.95
Support Level $6.26 $5.67
Resistance Level $6.79 $6.75
Average True Range (ATR) 0.37 0.88
MACD -0.14 0.01
Stochastic Oscillator 11.97 59.14

Price Performance

Historical Comparison
OPEN
IBRX

About OPEN Opendoor Technologies Inc

Opendoor Technologies Inc is an end-to-end real estate platform enabling customers to sell and buy a home online. Its product offerings include Sell to Opendoor, its core product where sellers sell their homes directly to the company, and it resells those homes to buyers; List with Opendoor, for customers to list their homes with a partner agent; and Opendoor Marketplace, a capital light marketplace offering that connects home sellers with both institutional and retail buyers. In addition to these products, the company also offers its customers integrated title insurance and escrow services through its subsidiaries. A vast majority of the company's revenue is generated by its core product offering, where it acquires homes directly from sellers and resells those homes to buyers.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Share on Social Networks: